The analysis revealed that about 2 per cent of sperm from men in their early 30s contained disease-causing mutations. That ...

Cancer is no longer considered untreatable, yet improving the accuracy and timeliness of diagnostics and treatment remains ...

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...

Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...

In perhaps the last public interview of one Israel's most famous VCs, Jon Medved tells TechCrunch how tech will enhance his life.

Researchers from the Peruvian National University Toribio Rodríguez de Mendoza (UNTRM) of Amazonas have made a fabulous scientific discovery: they have successfully sequenced and published the first ...

Inc42 and Shadowfax jointly kicked off the first edition of D2CX Converge in Hyderabad, bringing together over 50 early stage ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.

Deep beneath the ocean’s surface, a surprising discovery has revealed a giant creature thriving in the planet's most extreme and remote depths.

With the MiSeq™ i100 Series, Illumina continues to set the highest standards. Advancements in system design, sequencing chemistry, and data analysis deliver the simplest, fastest benchtop sequencing ...

One of the defining public health stories of 2025 was the return of diseases once thought to be under control. As the world ...